Fluticasone Furoate (27.5mcg) is a potent, synthetic, trifluorinated glucocorticoid receptor agonist, specifically formulated as an intranasal spray for the topical treatment of allergic rhinitis. It is a third-generation corticosteroid with enhanced lipophilicity and a higher affinity for the glucocorticoid receptor compared to earlier steroids like fluticasone propionate. The 27.5mcg per spray strength is a standard dose for once-daily administration, offering 24-hour symptom control with minimal systemic absorption, making it suitable for long-term management in the Indian climate where perennial allergens are common.
Adult: Adults (18 years and older): 110 mcg (2 sprays of 27.5 mcg per spray) in each nostril once daily (Total daily dose: 220 mcg). After symptoms are controlled, reduction to 55 mcg (1 spray per nostril) once daily may be effective for maintenance.
Note: 1. Shake the bottle gently before use. 2. Prime the pump by spraying into the air until a fine mist appears (for new bottle or if not used for 7+ days). 3. Blow nose gently to clear nostrils. 4. Close one nostril, tilt head slightly forward. 5. Insert nozzle into the other nostril, pointing slightly away from the nasal septum. 6. Breathe in gently through the nose while pressing down firmly on the applicator to release the spray. 7. Breathe out through the mouth. 8. Repeat for the other nostril. 9. Do not blow nose for 15 minutes after use. 10. Wipe the nozzle clean after each use.
Fluticasone furoate exerts potent anti-inflammatory and anti-allergic effects. It diffuses across cell membranes and binds with high affinity to cytoplasmic glucocorticoid receptors. The activated receptor complex translocates to the nucleus, where it modulates gene transcription by binding to glucocorticoid response elements (GREs) or by interacting with transcription factors like NF-ÎșB and AP-1.
Pregnancy: Pregnancy Category C (US FDA). Adequate and well-controlled studies in pregnant women are lacking. Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Topical administration minimizes systemic exposure.
Driving: No known effects on the ability to drive and use machines. However, if dizziness or visual disturbances occur, patients should avoid these activities.
| Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Itraconazole, Clarithromycin) | May significantly increase systemic exposure to fluticasone furoate, potentially increasing the risk of systemic corticosteroid adverse effects like Cushing's syndrome and adrenal suppression. | Major |
| Other Corticosteroids (Oral, Inhaled, Injectable) | Concomitant use increases the additive risk of hypothalamic-pituitary-adrenal (HPA) axis suppression and corticosteroid side effects. | Moderate |
Same composition (Fluticasone Furoate (27.5mcg)), different brands: